Economic Evaluation of Extended-release Injectable Naltrexone Compared to Buprenorphine-naloxone Initiated in Inpatient Settings for Treatment of Opioid Use Disorder
Results from a national clinical trial, X:BOT, published in January 2018, showed it was more difficult to initiate patients in inpatient and residential settings on extended-release naltrexone (XR-NTX) than buprenorphine naloxone (BUP-NX). Both medications were found to be equally safe and effective for those who successfully initiated treatment. Investigators and colleagues associated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) conducted primary and secondary economic analyses using data collected from X:BOT.
Quality of Life for SUD
Despite growing recognition that substance use disorder is a chronic disease, quality of life is rarely measured in substance use disorder treatment studies. With funding from the National Insitute on Drug Abuse (NIDA) R01DA033424, investigators measured the quality of life in prescription and injection opioid misuse using primary data from a survey of the US population and secondary data from opioid use disorder patients enrolled in three national treatment studies.